# US 2022/0033880 A1 · Epigenetic biomarker and uses therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033880 A1
- Document ID: US20220033880A1
- Status: Published application
- Kind: A1
- Application number: 17/286,379
- Filed: 2019-10-17
- Published: 2022-02-03
- Earliest claimed: 2018-10-17
- Assignees: The University of Queensland
- Applicants: The University of Queensland
- Inventors: Abu SINA; Matt TRAU; Laura GARCIA CARRASCOSA
- Web page: https://patentgrep.com/patent/US20220033880A1

## CPC

- C12Q 1/6809: Methods for determination or identification of nucleic acids involving differential detection
- C12Q 1/6825: Nucleic acid detection involving sensors
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/154: Methylation markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Disclosed is an epigenetic biomarker that comprises clustered methylated genomic DNA which can self-assemble to form complexes that have distinct physicochemical properties relative to genomic DNA that lacks such clusters. Also disclosed are methods, systems, compositions and kits that takes advantage of these physicochemical properties for detecting clustered methylated genomic DNA including for determining likelihood of the presence of cancer.

## Claims

### Claim 1

An isolated nucleic acid complex comprising genomic DNA comprising a plurality of genomic DNA molecules individual ones of which comprise a clustered distribution of methylated nucleotides, wherein the complex is formed by self-assembly of the DNA molecules under aqueous conditions.

### Claim at position 2

-9. (canceled)

### Claim 10

A system comprising:
a biological sample comprising a nucleic acid complex comprising genomic DNA comprising a plurality of genomic DNA molecules individual ones of which comprise a clustered distribution of methylated nucleotides, wherein the complex is formed by self-assembly of the DNA molecules under aqueous conditions; and
a sensor, which is in communication with the biological sample, for detecting the presence or level of the nucleic acid complex.

### Claim 11 (depends on 10)

The system of claim 10, wherein the sensor is selected from one or more of: an antigen-binding molecule that binds specifically with the nucleic acid complex, a light based sensor, a spectrometer, a refractometer, a particle sizer, an x-ray, a monochromator, an absorption detector, a reflectance detector, a transmission detector, a conductivity sensor, an electrode, a resistive pulse sensor, a camera, a microscope, a particle size analyzer, an optical detector, a solid support to which hydrophobic moieties adsorb under the aqueous conditions, a colloidal particle or a biosensor.

### Claim 12 (depends on 11)

The system of claim 11, wherein the microscope is a transmission electron microscope.

### Claim 13 (depends on 10)

The system of claim 10, wherein the sensor comprises a solid support to which hydrophobic moieties adsorb under the aqueous conditions.

### Claim 14 (depends on 13)

The system of claim 13, wherein the solid support comprises a carbon-based surface such as graphene or a metal substrate (e.g., gold (Au) substrate, a silver (Ag) substrate; a tin (Sn) substrate, a rhodium (Rh) substrate, a ruthenium (Ru) substrate, a palladium (Pd) substrate, an osmium (Os) substrate, an iridium (Ir) substrate, a platinum (Pt) substrate, a titanium (Ti) substrate, an aluminum (Al) substrate, a chromium (Cr), a copper (Cu) substrate, a magnesium (Mg) substrate, a carbon substrate, a silicon substrate such as p-type doped silicon substrate, n-type doped silicon substrate, and gallium arsenide), alloys thereof and composites thereof.

### Claim 15 (depends on 13)

The system of claim 13, wherein the solid support is a colloidal particle.

### Claim 16 (depends on 13)

The system of claim 13, wherein the sensor comprises an electrode that comprises an electro-conductive material to which hydrophobic moieties adsorb under the aqueous conditions.

### Claim 17 (depends on 16)

The system of claim 16, wherein the electro-conductive material is selected from gold, platinum, palladium, silver, carbon, alloys thereof, and composites thereof.

### Claim 18 (depends on 16)

The system of claim 16, wherein the electrode is a working electrode that is part of an electrical detection unit comprising an electrical circuit configured for detecting an electrical signal from the working electrode, wherein the electrical signal is selected from the group consisting of current or voltage, or a derived parameter such as impedance, capacitance, charge, conductivity, resistance, or a combination thereof.

### Claim at position 12

-82. (canceled)

### Claim 83

A method for detecting and measuring cancer DNA, the method comprising: exposing a biological sample comprising cancer DNA to a working electrode that comprises an electro-conductive material; applying a potential to the working electrode; and detecting an electrical signal from the working electrode that is indicative of adsorption of cancer DNA to the electroconductive material, wherein the electrical signal is different to an electrical signal generated from the working electrode when a corresponding normal DNA or a lesser amount of cancer DNA is adsorbed to the electroconductive material.

### Claim 84

(canceled)

### Claim 85 (depends on 83)

The method of claim 83, wherein the electro-conductive material is selected from gold, platinum, palladium, silver, carbon, alloys thereof, and composites thereof.

### Claim 86 (depends on 83)

The method of claim 83, wherein the electrical signal is selected from the group consisting of current, voltage, impedance, capacitance, charge, conductivity, resistance, or a combination thereof.

### Claim 87 (depends on 83)

The method of claim 83, wherein the biological sample is selected from tissue and fluid samples.

### Claim 88 (depends on 87)

The method of claim 87, wherein the biological sample is a tissue sample prepared by peeling cells using adhesive tape, scraping, or biopsy touch preparations.

### Claim 89 (depends on 88)

The method of claim 88, wherein the tissue sample is selected from the group consisting of lymph node, esophagus, lung, lung washes, BAL (bronchoalveolar lavage), thyroid, skin, breast, ovary, endometrium, uterus, pancreas, spleen, thymus, bone marrow, colon, stomach, bladder, brain, salivary gland, prostate, testicles and liver.

### Claim 90 (depends on 87)

The method of claim 87, wherein the biological sample is a biological fluid.

### Claim 91 (depends on 90)

The method of claim 90, wherein the biological fluid is selected from the group consisting of whole blood; lysed whole blood; serum; plasma; urine; sputum; sweat; follicular fluid; synovial fluid; amniotic fluid; a nasopharyngeal aspirate; a bronchial aspirate; semen and cerebrospinal fluid.

### Claim 92 (depends on 83)

The method of claim 83, wherein the cancer DNA and corresponding normal DNA is selected from the group consisting of cellular genomic DNA (cellular gDNA), cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), and extracellular vesicular DNA (evDNA).

### Claim at position 23

93-95. (canceled)
